Shanghai Hengrui Pharmaceutical Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Subsidiary

Established: 2001-12-04

Employees: -

Market Cap: -

Website: http://www.shhrp.com

Clinical Trials

Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management

Phase 2

Active, not recruiting

Conditions: Total Knee Arthroplasty

Interventions: Drug: HR18034;Ropivacaine Hydrochloride Injection

First Posted Date: 2022-09-30

Last Posted Date: 2024-03-04

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 89

Registration Number: NCT05561309

Locations: 🇨🇳
Dongguan People's Hospital, Dongguan, Guangdong, China

Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

Phase 2

Completed

Conditions: Moderate to Severe Atopic Dermatitis

Interventions: Drug: Placebo
Drug: SHR1819

First Posted Date: 2022-09-22

Last Posted Date: 2024-01-23

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 158

Registration Number: NCT05549947

Locations: 🇨🇳
Huashan Sub-Hospital of Fudan University, Shanghai, Shanghai, China

A Study of HR19024 in Subjects With Advanced Solid Tumor

Phase 1

Conditions: Advanced Solid Tumor

Interventions: Drug: HR19024

First Posted Date: 2022-07-19

Last Posted Date: 2022-09-01

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 180

Registration Number: NCT05463432

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of SHR-1501 Alone or in Combination With BCG in Subjects With NMIBC

Phase 1

Recruiting

Conditions: High-risk NMIBC

Interventions: Drug: SHR-1501

First Posted Date: 2022-06-08

Last Posted Date: 2024-08-01

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT05410730

Locations: 🇨🇳
Peking University First Hospital, Beijing, Beijing, China

A Trial of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy.

Phase 2

Completed

Conditions: Postsurgical Pain Management

Interventions: Drug: HR18034
Drug: ropivacaine HCl.

First Posted Date: 2022-05-17

Last Posted Date: 2023-03-20

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 86

Registration Number: NCT05376904

Locations: 🇨🇳
Li Huili Hospital of Ningbo Medical Center, Ningbo, Zhejiang, China
🇨🇳
Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

and more 15 locations

A Trial of SHR6508 in Secondary Hyperparathyroidism

Phase 1

Completed

Conditions: Secondary Hyperparathyroidism

Interventions: Drug: SHR6508；Placebo

First Posted Date: 2022-02-02

Last Posted Date: 2023-08-08

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 54

Registration Number: NCT05221008

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

Clinical Study on the Efficacy and Safety of Multiple Oral Administrations of SHR2285 Tablets in Patients Undergoing Elective Total Knee Arthroplasty

Phase 2

Conditions: Prevention of Venous Thrombosis After TKA

Interventions: Drug: SHR2285 tablet
Drug: Enoxaparin

First Posted Date: 2022-01-24

Last Posted Date: 2022-03-21

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 500

Registration Number: NCT05203705

Locations: 🇨🇳
Perking Union Medical College Hospital, Beijing, Beijing, China

A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Phase 1

Conditions: Moderate to Severe Atopic Dermatitis

Interventions: Drug: SHR-1819 injection or placebo

First Posted Date: 2022-01-19

Last Posted Date: 2022-01-19

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT05197023

A Study of SHR-A1909 in Subjects With Advanced Malignant Tumors

Phase 1

Conditions: Advanced Malignant Cancer

Interventions: Drug: SHR-1909 injection

First Posted Date: 2021-12-17

Last Posted Date: 2022-03-02

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 100

Registration Number: NCT05162469

Locations: 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China

A First-in-human Study of HRS2398 Tablets in Subjects With Advanced Malignant Tumors

Phase 1

Completed

Conditions: Advanced Malignant Tumor

Interventions: Drug: HRS2398 Tablets

First Posted Date: 2021-12-03

Last Posted Date: 2024-12-18

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 28

Registration Number: NCT05144061

Locations: 🇨🇳
Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, Henan, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy